More than 50 biotech leaders and investors are urging the FDA to disregard a methodologically flawed report on mifepristone.

Our health care system needs to do a better job of diagnosing and supporting people with cannabis-related diseases,” a ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

The people most at risk from suicide aren’t adolescents in angst or those experiencing a midlife lull, but men age 75 and ...

Robert F. Kennedy Jr. just named Mark Cruz, a Klamath member, his top tribal health adviser. In a Q&A, Cruz emphasized tribal ...

A federal judge has tossed out a lawsuit from Humana that attempted to reinstate higher quality ratings to its 2025 Medicare ...

The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...

A new large study from Denmark finds no evidence that aluminum salts used in vaccines are tied to a higher risk of childhood ...

A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...

Many of the 17 million projected to lose Medicaid coverage will turn to struggling free health clinics. They need more ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...